Xtant Medical (XTNT) to Release Quarterly Earnings on Tuesday

Key Points

• Xtant Medical (XTNT) will release its quarterly earnings on August 12th, with analysts anticipating a loss of $0.02 per share and revenues of approximately $31.35 million.
• The stock of Xtant Medical has seen an increase of 3.8%, trading at $0.57 during mid-day, with a market capitalization of $79.72 million.
• Xtant Medical specializes in regenerative medicine products and medical devices aimed at orthopedic and neurological procedures.

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $31.35 million for the quarter.

Xtant Medical Stock Performance

Shares of XTNT traded down $0.01 during trading hours on Friday, reaching $0.62. 15,798 shares of the company's stock traded hands, compared to its average volume of 50,695. The firm has a market capitalization of $86.38 million, a price-to-earnings ratio of -6.89 and a beta of -0.21. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.34 and a quick ratio of 1.03. Xtant Medical has a twelve month low of $0.33 and a twelve month high of $0.78. The business's fifty day simple moving average is $0.64 and its two-hundred day simple moving average is $0.56.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.